

## **CONTRIBUTION OF DISRUPTION OF THE NF- $\kappa$ B PATHWAY TO INDUCTION OF APOPTOSIS IN HUMAN LEUKEMIA CELLS BY HISTONE DEACETYLASE INHIBITORS AND FLAVOPIRIDOL**

Ning Gao, Yun Dai, Mohamed Rahmani, Paul Dent, Steven Grant¶

Departments of Medicine (N.G., Y.D., M.R., S.G.), Biochemistry (S.G.), Pharmacology (S.G.), and Radiation Oncology (P.D.), Virginia Commonwealth University/Medical College of Virginia, Richmond, VA, 23298

## NF- $\kappa$ B and HDAC inhibitors/flavopiridol-mediated apoptosis

¶ To whom correspondence should be addressed as follows:

Dr. Steven Grant  
Division of Hematology/Oncology  
Virginia Commonwealth University/Medical College of Virginia  
MCV Station Box 230  
Richmond, VA 23298

Phone: 804-828-5211  
Fax: 804-828-8079  
Email: [stgrant@hsc.vcu.edu](mailto:stgrant@hsc.vcu.edu)

Number of text pages: 30

Number of figures: 7

Number of References: 40

Number of words in Abstract: 232; Introduction: 750; Discussion: 1125

The abbreviations used are: CDKI, cyclin-dependent kinase inhibitor; HDACIs, histone deacetylase inhibitors; FP, flavopiridol; NaB, sodium butyrate; SAHA, suberoylanilide hydroxamic acid; NF- $\kappa$ B, Nuclear factor-kappaB; IKK, IkappaB kinase; EMSA, electrophoretic mobility shift assay.

## ABSTRACT

Interactions between the cyclin-dependent kinase inhibitor (CDKI) flavopiridol and the histone deacetylase inhibitors (HDACIs) sodium butyrate (NaB) and SAHA have been examined in human leukemia cells in relation to effects on NF- $\kappa$ B activation. Exposure (24 hr) of U937 human leukemia cells to NaB (1 mM) or SAHA (1.5  $\mu$ M) resulted in a marked increase in NF- $\kappa$ B DNA binding, effects that were essentially abrogated by co-administration of flavopiridol (100 nM). These events were accompanied by a marked increase in mitochondrial injury, caspase activation, and apoptosis. Mutant cells expressing an I $\kappa$ B $\alpha$  super-repressor exhibited impairment of NF- $\kappa$ B DNA binding in response to HDACIs and a significant although modest increase in apoptosis. However, disruption of the NF- $\kappa$ B pathway also increased mitochondrial injury and caspase activation in response to flavopiridol and to an even greater extent to the combination of flavopiridol and HDACIs. Co-administration of flavopiridol with HDACIs down-regulated XIAP, Mcl-1, and p21<sup>CIP1/WAF1</sup> and activated JNK; moreover, these effects were considerably more pronounced in I $\kappa$ B $\alpha$  mutants. Similar responses were observed in U937 mutant cells stably expressing RelA/p65 siRNA. In all cases, flavopiridol was significantly more potent than genetic interruption of the NF- $\kappa$ B cascade in promoting HDACI-mediated lethality. Together, these findings are consistent with the notion that while inhibition of NF- $\kappa$ B activation by flavopiridol contributes to antileukemic interactions with HDACIs, other NF- $\kappa$ B-independent flavopiridol actions (e.g., down-regulation of Mcl-1, XIAP, and p21<sup>CIP1/WAF1</sup>) play particularly critical roles in this phenomenon.

## INTRODUCTION

Histone acetylation status plays a major role in the control of gene transcription in diverse cell types, including those of leukemic origin (Carrozza et al., 2003). Histones acetylation is reciprocally regulated by two classes of enzymes: histone deacetylases (HDAC) and histone acetyl transferases (HATs) (Peterson, 2002). In general, acetylation of histones allows chromatin to assume a more relaxed conformation, thereby promoting gene transcription (Gray and Teh, 2001). Histone deacetylase inhibitors (HDACIs) represent a diverse group of compounds that block histone deacetylation, and thereby modulate expression of genes involved in multiple cellular processes, including differentiation (Rosato and Grant, 2004). In leukemic cells, HDACIs including the short chain fatty acid butyrate and the hydroxamic acid suberoylanilide hydroxamic acid (SAHA) potently induce differentiation *in vitro* (Rivero and Adunyah, 1998; Richon et al., 1998). However, when administered at higher concentrations, such agents trigger leukemic cell apoptosis (Vrana et al., 1999). Recently it has been shown that dysregulation of the endogenous cyclin-dependent kinase inhibitor p21<sup>CIP1/WAF1</sup> in human leukemia cells blocks HDACI-mediated maturation and reciprocally promotes cell death (Rahmani et al, 2003). Clinical trials of butyrate derivatives (e.g., phenylbutyrate) have been carried out in patients with hematologic malignancies (Gilbert et al., 2001), and Phase I and II trials of SAHA are underway (Kelly et al., 2003).

Flavopiridol, a semi-synthetic rohitukine alkaloid that potently inhibits essentially all cyclin-dependent kinases (CDKs) (De Azevedo et al., 1996), was the first CDK inhibitor to enter clinical trials (Senderowicz, 1999). Flavopiridol induces G<sub>1</sub> arrest in tumor cells (Carlson et al., 1996), and triggers leukemic cell apoptosis at sub-micromolar concentrations (Parker et al., 1998). Recently, flavopiridol has been reported to inhibit the cyclin T/CDK9 transcriptional regulatory complex (Positive Transcription Elongation Factor-b; PTEF-b) (Chao et al., 2000)

and to repress transcription of various genes, including p21<sup>CIP1/WAF1</sup> and Mcl-1 among others (Rosato et al., 2004, Gojo et al., 2002). Very recently, flavopiridol has been shown to inhibit activation of NF- $\kappa$ B, a transcription factor intimately involved in diverse cellular processes, including cell survival, proliferation, and differentiation (Takada and Aggarwal, 2004). NF- $\kappa$ B regulation involves, among other mechanisms, sequestration in the cytoplasm as an inactive form by members of the I $\kappa$ B family (e.g., I $\kappa$ B $\alpha$ ) (Goldberg and Rock, 2002). Recently, flavopiridol has been shown to disrupt NF- $\kappa$ B signaling by inhibiting the IKK kinase, thus sparing I $\kappa$ B $\alpha$  from proteasomal degradation (Takada and Aggarwal, 2004). The role that flavopiridol-mediated interruption of NF- $\kappa$ B signaling plays in antileukemic interactions remains largely unexplored.

Studies from several groups have shown that co-administration of flavopiridol with HDACIs such as sodium butyrate (NaB), SAHA, and depsipeptide dramatically increases mitochondrial injury and apoptosis in leukemic and epithelial cancer cells (Almenara et al., 2002, Rosato et al., 2004, Nguyen et al., 2004). It has been postulated that such interactions may stem from flavopiridol-mediated transcriptional repression of anti-apoptotic genes (e.g., p21<sup>CIP1/WAF1</sup>, Mcl-1, XIAP) (Almenara et al., 2002; Rosato et al., 2004). However, it is also known that HDACIs trigger perturbations in NF- $\kappa$ B activity, and that such events may protect cells from apoptosis. For example, HDACIs such as trichostatin A (TSA) and sodium butyrate (NaB) activate NF- $\kappa$ B in non-small cell lung cancer cells; moreover, pharmacologic or genetic NF- $\kappa$ B inhibition promotes HDACI-mediated apoptosis (Mayo et al., 2003). Analogously, disruption of the NF- $\kappa$ B pathway in human leukemia cells blocks HDACI-mediated p21<sup>CIP1/WAF1</sup> induction, inhibits differentiation, and enhances apoptosis (Dai et al., 2003a). Such findings raise the possibility that an intact NF- $\kappa$ B pathway may be required for HDACIs and other differentiation-inducing agents to trigger a maturation program in malignant hematopoietic cells.

Because NF- $\kappa$ B activation is required for leukemic cell maturation (Dai et al., 2003a), and in view of recent evidence that flavopiridol acts as an IKK inhibitor (Takada and Aggarwal, 2004), the possibility that flavopiridol-mediated NF- $\kappa$ B inhibition might contribute to synergistic interactions with HDACIs appeared plausible. To define the role that flavopiridol-mediated NF- $\kappa$ B dysregulation might play in antileukemic synergism more rigorously, we have examined interactions between flavopiridol and the HDACIs NaB and SAHA in relation to effects on NF- $\kappa$ B activation. Specifically, we have employed genetic strategies to assess the functional significance of perturbations in NF- $\kappa$ B activation on mitochondrial injury, caspase activation, and cell survival following exposure of cells to these agents alone and in combination. Our results indicate that flavopiridol dramatically blocks HDACI-mediated NF- $\kappa$ B activation in human leukemia cells and that this event plays a significant, albeit limited, role in antileukemic synergism. However, our findings also suggest that interactions between these agents are multifactorial, and that more direct, NF- $\kappa$ B-independent flavopiridol actions (e.g., down-regulation of p21<sup>CIP1/WAF1</sup>, Mcl-1, and XIAP) in all likelihood contribute substantially to this phenomenon.

## MATERIALS AND METHODS

### Reagents and Cell Culture

The pan-CDK inhibitor, flavopiridol, was kindly provided by Dr Edward Sausville (Division of Cancer Treatment, NCI/NIH, Bethesda, MD). Sodium butyrate (NaB) was purchased from Biomol (Plymouth Meeting, PA), and suberoylanilide hydroxamic acid (SAHA) was purchased from Biovision (Mountain View, CA). All reagents were dissolved in DMSO as a stock solution and stored at  $-80^{\circ}\text{C}$ .

U937 human leukemia cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured in RPMI 1640 medium supplemented with sodium pyruvate, MEM, essential vitamins, L-glutamine, penicillin, streptomycin, and 10% fetal bovine serum (FBS). U937 cells were stably transfected with Ser32/Ser36 mutant  $\text{I}\kappa\text{B}\alpha$  cDNA or an empty vector (pcDNA3.1), and clones were selected with G418 as previously reported (Dai et al., 2003). All experiments were performed using logarithmically growing cells ( $3\text{-}5 \times 10^5$  cells/ml).

RelA/p65 siRNA-expressing U937 cells were obtained by standard transfection techniques. The DNA oligonucleotides encoding hairpin siRNA targeting the coding region 186–204 downstream of the first nucleotide of the start codon of human relA/p65 were designed using the siRNA Target Finder tool (Ambion). Two complementary DNA oligonucleotides

**(5'gatccGATCAATGGCTACACAGGAttcaagaga**

**TCCTGTGTAGCCATTGATCtttttggaaa-3')and (3'gCTAGTTACCGATGTGTCCT**

**aagtctctAGGACACATCGGTAAGTAACTAGaaaaaaccttttcga-5')** were synthesized, annealed and

cloned into bamHI/HindIII sites of The RNA polymerase III-based expression vector *psilencer 3.1-H1 hygro* (3.1-H1 hygro-p65siRNA) using standard techniques. The construct was verified by DNA sequencing and transfected into U937 cells using electroporation as previously

described (Rahmani et al., 2003). Stable clones from a single cell were selected in the presence of 400 µg/ml of hygromycin and tested for p65 protein expression by Western blot.

### **Annexin V/PI Assays for Apoptosis**

For Annexin V/PI assays, cells were stained with Annexin V-FITC and propidium iodide (PI), and evaluated for apoptosis by flow cytometry according to the manufacturer's protocol (BD PharMingen, San Diego, CA). Briefly,  $1 \times 10^6$  cells were washed twice with PBS, and stained with 5 µl of Annexin V-FITC and 10 µl of PI (5 µg/ml) in 1× binding buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 mM CaCl<sub>2</sub>) for 15 min at room temperature in the dark. The apoptotic cells were determined using a Becton Dickinson FACScan cytofluorometer (Mansfield, MA).

### **Western Blot Analysis**

Western blot analysis was performed using the NuPAGE Bis-Tris electrophoresis system (Invitrogen, Carlsbad, CA). The total cellular samples were washed twice with cold phosphate-buffered saline (PBS) and lysed in 1× NuPAGE LDS sample buffer supplemented with 50 mM dithiothreitol (DTT, Fisher Biotech, Pittsburgh, PA). The protein concentration was determined using Coomassie Protein Assay Reagent (Pierce, Rockford, IL). The total cellular protein extracts were separated by SDS-PAGE, and transferred to nitrocellulose membrane in 20 mM Tris-HCl (pH 8.0) containing 150 mM glycine and 20% (v/v) methanol. Membranes were blocked with 5% nonfat dry milk in 1× TBS containing 0.05% Tween 20 and incubated with antibodies against phosphor-JNK (Thr183/Tyr185)(Santa Cruz, Santa Cruz, CA), SAPK/JNK (Cell Signaling, Beverly, MA), XIAP (Cell Signaling), Mcl-1 (PharMingen, San Diego, CA), p21<sup>WAF1/CIP1</sup> (Transduction Laboratories, Lexington, KY), p27<sup>KIP1</sup> (PharMingen), PARP



(Biomol, Plymouth Meeting, PA), cleaved caspase-3 (Cell Signaling), caspase-8 (Alexis, Carlsbad, CA), caspase-9 (PharMingen).  $\beta$ -Actin (Santa Cruz) was used to ensure equal loading and transfer of proteins. Protein bands were detected by incubating with horseradish peroxidase-conjugated antibodies (Kirkegaard and Perry Laboratories, Gaithersburg, MD), and visualized with enhanced chemiluminescence reagent (PerkinElmer Life Sciences, Boston, MA).

### **Analysis of Cytosolic Cytochrome C and AIF**

After treatment, cells ( $2 \times 10^6$ ) were washed twice in PBS and lysed by incubating for 5 min in lysis buffer (75 mM NaCl, 8 mM  $\text{Na}_2\text{HPO}_4$ , 1 mM  $\text{NaH}_2\text{PO}_4$ , 1 mM EDTA, and 350  $\mu\text{g/ml}$  digitonin). The lysate was centrifuged for 1 min, and the supernatant was collected and added to an equal volume of 2 $\times$  sample buffer. The protein concentration was determined using Coomassie Protein Assay Reagent (Pierce, Rockford, IL). 30  $\mu\text{g}$  of cytosolic extract was separated by SDS-PAGE, transferred to nitrocellulose membrane, and incubated with antibodies against cytochrome C (PharMingen) and AIF (Santa Cruz).

### **Electrophoretic Mobility Shift Assay (EMSA)**

Nuclear protein extracts were prepared as previously described (Hehner et al., 1998). Briefly, cells were harvested and resuspended in hypotonic buffer A (10 mM HEPES, pH 7.9, 1.5 mM  $\text{MgCl}_2$ , 10 mM KCl, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1  $\mu\text{g/ml}$  leupeptin, and 1  $\mu\text{g/ml}$  aprotinin) for 15 min on ice and then added 5  $\mu\text{l}$  of 10% Nonidet P-40. After centrifugation at 2,000 g for 10 min at 4°C, nuclei pellets were resuspended in buffer B (20 mM HEPES, pH 7.9, 1.5 mM  $\text{MgCl}_2$ , 450 mM NaCl, 0.2 mM EDTA, 25% glycerol, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1  $\mu\text{g/ml}$  leupeptin, and 1  $\mu\text{g/ml}$  aprotinin) for 30 min on ice. After centrifugation at 20,000 g for 15 min, the supernatant was collected as the

nuclear extracts, and stored at  $-70^{\circ}\text{C}$ . For EMSA, 4  $\mu\text{g}$  of nuclear extracts were incubated with DNA binding buffer containing 2  $\mu\text{g}$  of poly(dI-dC), 1  $\mu\text{g}$  of bovine serum albumin, and 15,000 cpm of a  $^{32}\text{P}$ -labeled oligonucleotide. Subsequently the free and the oligonucleotide-bound proteins were separated by electrophoresis on a native 6% polyacrylamide gel. The gel was dried after electrophoresis and exposed to an X-ray film. The following oligonucleotide corresponding to NF- $\kappa\text{B}$  binding site was used: 5'-AGTTGAGGGGACTTTCCCAGGC-3'/3'-TACTCTCCCCTGAAAGGGTCCG-5'.

### **Densitometric Analysis**

Autoradiographic signals of EMSA were quantified using Scion Image software (Scion Corporation). Mean densitometry data from independent experiments were normalized to results obtained in cells in the control. The data were presented as the mean  $\pm$  SD.

### **Statistical Analysis**

For analysis of apoptosis, values were presented as means  $\pm$  SD. Statistical differences between control and treated groups were determined by the Student's t-test. Differences were considered statistically significant for values of  $p < 0.05$ ,  $p < 0.01$  and  $p < 0.001$ .

## RESULTS

### **Flavopiridol blocks SAHA- and NaB-mediated induction of NF- $\kappa$ B DNA-binding activity**

To assess the effects of flavopiridol on NF- $\kappa$ B activation by HDACIs, U937 cells were exposed to 1 mM NaB or 1.5  $\mu$ M SAHA for 24 hr in the presence or absence of 100 nM flavopiridol, after which NF- $\kappa$ B DNA binding was monitored by EMSA analysis (Figure 1) and quantified by densitometry. Both SAHA and NaB markedly increased while flavopiridol slightly decreased basal NF- $\kappa$ B DNA binding (Figures 1A and 1B). Significantly, flavopiridol dramatically reduced HDACI-mediated NF- $\kappa$ B activation. Supershift assays employing antibodies directed against p50 and p65 confirmed the specificity of these events (Figure 1C). These findings indicate that co-administration of flavopiridol prevents NaB- and SAHA-mediated NF- $\kappa$ B activation in U937 cells.

### **Expression of an I $\kappa$ B $\alpha$ “super-repressor” abrogates NF- $\kappa$ B activation in cells exposed to HDACIs $\pm$ flavopiridol**

To investigate the effects of interruption of the NF- $\kappa$ B pathway on the response of cells to HDACIs  $\pm$  flavopiridol, U937 cells ectopically expressing an I $\kappa$ B $\alpha$  super-repressor mutant were employed. This construct exhibits serine to alanine substitutions at residues 32 and 36, which prevent proteasomal degradation of I $\kappa$ B, allowing this protein to bind and inactivate NF- $\kappa$ B in the cytoplasm (Alkalay et al., 1995). As shown in Figure 2A and 2B, expression of the I $\kappa$ B $\alpha$  super-repressor by two separate clones (2C8 and 2H6) substantially reduced NF- $\kappa$ B DNA binding in cells exposed to HDACIs alone, and essentially abrogated DNA binding in cells exposed to flavopiridol alone or in combination.

## **Genetic blockade of NF- $\kappa$ B activation potentiates apoptosis by HDACIs, flavopiridol, as well as the HDACI/flavopiridol combination**

The impact of genetic interruption of the NF- $\kappa$ B cascade on the apoptotic response of U937 cells to HDACIs  $\pm$  flavopiridol was then investigated. The central premise underlying these studies was that if NF- $\kappa$ B disruption played a critical role in synergistic interactions between flavopiridol and HDACIs, then such synergism would be attenuated in mutant cells (because NF- $\kappa$ B was already disrupted). Several findings emerged from these studies. First, both mutant clones displayed a modest but statistically significant increase ( $p < 0.01$  in each case) in apoptosis in response to low, minimally toxic concentrations of either NaB or SAHA (Figure 3A and 3B). Second, disabling of the NF- $\kappa$ B pathway markedly increased the lethal effects of flavopiridol, consistent with our earlier findings (Dai et al., 2003b). Interestingly, apoptosis in I $\kappa$ B $\alpha$  mutant cells exposed to flavopiridol + HDACIs was essentially complete, and in all cases modestly but significantly greater than that exhibited by empty vector controls ( $p < 0.01$  for all conditions). Finally, potentiation of NaB- or SAHA-mediated apoptosis by flavopiridol was significantly greater than that observed in I $\kappa$ B $\alpha$  mutant cells ( $p < 0.01$  in all cases). Collectively, these findings argue that while flavopiridol-related inhibition of HDACI-mediated NF- $\kappa$ B activation may contribute to the marked increase in apoptosis in HDACI/flavopiridol-treated cells, other flavopiridol actions, presumably unrelated to effects on NF- $\kappa$ B, very likely play a role in this phenomenon.

## **Effects of disruption of the NF- $\kappa$ B cascade on mitochondrial injury and caspase activation in U937 cells**

Effects of disabling the NF- $\kappa$ B cascade were then investigated in relation to induction of mitochondrial injury and apoptosis by HDACIs  $\pm$  flavopiridol. To this end, empty vector (pcDNA 3.1) and mutant clones (2C8 and 2H6) were exposed to NaB or SAHA  $\pm$  flavopiridol as above, after which release of cytochrome c or AIF into the cytosolic S-100 fraction or cleavage/activation of caspases were monitored by Western blot analysis. As shown in Figure 4A and 4B, I $\kappa$ B $\alpha$  mutant cells displayed modest increases in cytochrome c and AIF release in response to flavopiridol. On the other hand, exposure to NaB (4A) or SAHA (4B) alone had either no or a very limited effect on cytochrome C/AIF release in mutant cells. However, I $\kappa$ B $\alpha$  mutants exhibited a slight but discernible increase in cytochrome c and a more pronounced increase in AIF release in response to the combination of HDACIs + flavopiridol. Combined treatment with HDACIs + flavopiridol also resulted in enhanced activation/cleavage of caspases-3, -8, and -9 in I $\kappa$ B $\alpha$  transfectants (Figures 5A and 5B). As observed in the case of apoptosis, Flavopiridol was more effective than blockade of the NF- $\kappa$ B pathway in potentiating HDACI-mediated mitochondrial injury. This finding, along with evidence that genetic interruption of the NF- $\kappa$ B pathway potentiates HDACI/flavopiridol-induced mitochondrial injury, caspase activation, and apoptosis, argue that factors other than or in addition to flavopiridol-mediated NF- $\kappa$ B inhibition contribute to the pronounced induction of apoptosis by this drug combination.

### **Leukemia cells stably expressing RelA/p65 siRNA display enhanced apoptosis in response to the HDACI/flavopiridol regimen**

To determine whether these findings were restricted to cells expressing the I $\kappa$ B $\alpha$  mutant protein, parallel studies were performed in leukemia cells stably expressing a RelA/p65 siRNA construct. As shown in Figure 6A, transfectants cells displayed a marked reduction in expression of RelA/p65 compared to their empty vector controls. Furthermore, mutant cells showed a

significant increase in susceptibility to flavopiridol-induced apoptosis (Figures 6B and 6C). Moreover, expression of the RelA/p65 antisense construct resulted in modest but statistically significant increases ( $P < 0.01$  in each case) in the apoptotic responses of cells to low, marginally toxic concentrations of NaB or SAHA. As noted in the case of I $\kappa$ B $\alpha$  mutants, these effects were clearly less pronounced than those attributable to flavopiridol alone in control cells. Also consistent with results observed in I $\kappa$ B $\alpha$  mutants, RelA/p65 siRNA-expressing cells were significantly more sensitive to flavopiridol than controls ( $p < 0.01$ ). Finally, cells expressing the siRNA construct resulted in a modest but statistically significant ( $p < 0.01$ ) increase in apoptosis following exposure to the flavopiridol/HDACI regimen. Collectively, these findings provide further support for the notion that factors in addition to disruption of the NF- $\kappa$ B pathway contribute to the dramatic antileukemic synergism observed between flavopiridol and HDACIs.

### **Disruption of the NF- $\kappa$ B cascade promotes JNK activation and down-regulation of XIAP, Mcl-1, and p21<sup>CIP1/WAF1</sup> in response to flavopiridol/HDACIs**

The effects of disabling the NF $\kappa$ B cascade were then examined in relation to perturbations in stress and cell cycle-related pathways. Similar to results described above, I $\kappa$ B $\alpha$  mutant cells displayed minimal increases in activation of the stress kinase JNK in response to NaB or SAHA alone, and modest increases in flavopiridol-mediated JNK activation (Figure 7). However, disabling of the NF- $\kappa$ B axis markedly increased JNK activation in response to flavopiridol/HDACIs. In separate studies, co-administration of the JNK inhibitor SP600125 (10  $\mu$ M) failed to attenuate flavopiridol/HDACI-mediated lethality (data not shown), arguing against a major functional role for JNK activation in this phenomenon.

Flavopiridol modestly diminished XIAP expression in parental cells, and this effect was also observed in I $\kappa$ B $\alpha$  mutants. In contrast, HDACIs had little effect on XIAP expression in any

of the cell lines. However, XIAP expression was substantially reduced in parental cells and essentially abrogated in mutant cells treated with flavopiridol/HDACIs. Expression of the anti-apoptotic protein Mcl-1 was modestly reduced by flavopiridol alone, and either unchanged or slightly increased in cells treated with HDACIs. However, expression was absent in mutant cells exposed to flavopiridol/HDACIs. Both NaB and SAHA induced p21<sup>CIP1/WAF1</sup> and this response was attenuated by either flavopiridol or by expression of the IκBα mutant protein. Furthermore, p21<sup>CIP1/WAF1</sup> expression was essentially abrogated in mutant cells treated with the flavopiridol/HDACI regimen. Combined exposure to flavopiridol/HDACIs also resulted in cleavage and reduced expression of p27<sup>KIP1</sup>, events that were more pronounced in IκBα mutant cells. Finally, the effects of flavopiridol on XIAP, Mcl-1, and p21<sup>CIP1/WAF1</sup> down-regulation in wild-type cells were in all cases greater than those triggered by disruption of the NF-κB pathway i.e., by expression of IκBα mutants. Together, these findings suggest that while disabling the NF-κB pathway by flavopiridol may contribute to perturbations in certain stress, cell cycle, and survival pathways in HDACI-treated cells, other events, including those related to direct actions of flavopiridol, are more likely to play primary roles in the dramatic antileukemic synergism between these agents.

## DISCUSSION

The concept of combining pharmacologic CDK inhibitors such as flavopiridol with differentiation-inducing agents such as HDACIs in leukemia therapy has several theoretical rationales. For example, HDACIs have been shown to be potent inducers of leukemic cell differentiation (Rosato et al., 2003). In addition, induction of leukemic cell maturation requires cells to undergo G<sub>1</sub> arrest (Dai et al., 2003a); moreover, CDK inhibitors, including flavopiridol, have been reported to induce differentiation in certain malignant cell types (e.g., non-small cell lung cancer cells) (Lee et al., 1999). Thus, the possibility that flavopiridol might enhance maturation by HDACIs as well as other maturation-inducers appeared plausible. However, it has been established that flavopiridol does not promote HDACI-mediated differentiation; instead, flavopiridol has been shown to potentiate mitochondrial injury and apoptosis by multiple HDACIs including NaB, SAHA, and depsipeptide (Almenara et al., 2002; Rosato et al., 2004, Nguyen et al., 2004). This capacity has been attributed to the ability of flavopiridol to diminish, via inhibition of the PTEF-b CDK9/cyclin T complex (Chao et al., 2000), expression of various anti-apoptotic proteins, including Mcl-1, XIAP, and p21<sup>CIP1/WAF1</sup>, which are necessary for the normal maturation program to proceed. Recently, several other potentially pro-apoptotic flavopiridol actions have been described, including inhibition of survivin phosphorylation (Wall et al., 2003) and disruption of the NF-κB pathway through inhibition of the IKK kinase (Sizemore et al., 2002). In this regard, HDACIs have been shown to activate NF-κB (Dai et al., 2003a; Adam et al., 2003), an action which under some circumstances blocks HDACI-mediated apoptosis (Mayo et al., 2003). Furthermore, in human leukemia cells, disruption of NF-κB signaling by either pharmacologic or genetic means disrupts differentiation-induction by phorbol esters (Altuwaijri et al., 2003) as well as HDACIs (Dai et al., 2003a), resulting in a reciprocal increase in apoptosis. Based upon these considerations, it is tempting to speculate that



flavopiridol-mediated NF- $\kappa$ B inhibition may contribute to synergistic antileukemic interactions that occur between this agent and HDACIs.

The results presented here indicate that NaB and SAHA do in fact strikingly activate NF- $\kappa$ B in U937 human leukemia cells, and that this action is largely abrogated by co-administration of flavopiridol. However, while flavopiridol-mediated inhibition of HDACI-associated NF- $\kappa$ B activation in all likelihood contributes to potentiation of apoptosis by this drug combination, other actions undoubtedly play a major role in this phenomenon. For example, consistent with previous results by our group and others (Dai et al., 2003b, Mayo et al., 2003), disabling of the NF- $\kappa$ B pathway significantly increased, albeit modestly, HDACI-mediated lethality, even when the latter was administered at low, marginally toxic concentrations. However, potentiation of HDACI-mediated apoptosis by flavopiridol was significantly greater than that induced by genetic interruption of the NF- $\kappa$ B pathway (e.g., in cells expressing the I $\kappa$ B $\alpha$  mutant protein or RelA/p65 siRNA). In addition, genetic disruption of NF- $\kappa$ B signaling resulted in a significant increase in cell death in leukemic cells exposed to the flavopiridol/HDACI regimen. Because the NF- $\kappa$ B pathway is already disrupted in mutant cells, this finding indicates that factors other than or in addition to flavopiridol-mediated NF- $\kappa$ B inhibition is involved in lowering the apoptotic threshold. Collectively, these observations suggest that while the striking ability of flavopiridol to block HDACI-mediated NF- $\kappa$ B activation very likely contributes to the observed potentiation of apoptosis, other flavopiridol actions, particularly those unrelated to NF- $\kappa$ B inhibition, play a critical role in this interaction.

One possible explanation for the present observations is that flavopiridol may modulate the expression of proteins involved in regulation of HDACI-mediated apoptosis through both NF- $\kappa$ B-dependent as well as –independent mechanisms. For example, the endogenous cyclin-dependent kinase inhibitor p21<sup>CIP1/WAF1</sup> is a major target of HDACIs (Gui et al., 2004) and has

been shown in multiple systems to attenuate HDACI-mediated apoptosis (Almenara et al., 2002; Rosato et al., 2003, Nguyen et al., 2004). The latter capacity may reflect, at least in part, the ability of cytoplasmic p21<sup>CIP1/WAF1</sup> to bind to and inactivate procaspase-3 (Asada et al., 1999; Rosato et al., 2004). However, a functional role for NF- $\kappa$ B activation in induction of p21<sup>CIP1/WAF1</sup> in human leukemia cells exposed to phorbol esters and HDACIs has recently been demonstrated (Dai et al., 2003a). Thus, abrogation of p21<sup>CIP1/WAF1</sup> induction and potentiation of apoptosis in HDACI-treated cells by flavopiridol may reflect both direct effects related to flavopiridol-mediated transcriptional repression, e.g., through inhibition of PTEF-b (Chao et al., 2000), as well as indirect effects i.e., mediated by inhibition of NF- $\kappa$ B. In support of this notion, p21<sup>CIP1/WAF1</sup> induction by NaB or SAHA was attenuated in I $\kappa$ B $\alpha$  mutant cells, but was essentially abrogated when flavopiridol was added. Similar considerations apply to the anti-apoptotic protein XIAP, which is both a target of NF- $\kappa$ B (Tang et al., 2001) as well as of flavopiridol (Dai et al., 2003b). Finally, it is conceivable that the lethal consequences of disruption of NF- $\kappa$ B activation by flavopiridol may be potentiated by down-regulation of certain anti-apoptotic proteins (e.g., Mcl-1) through a direct, NF- $\kappa$ B-independent mechanism.

Combined treatment with flavopiridol and HDACIs resulted in a clear increase in mitochondrial injury (e.g., cytochrome c and AIF release), particularly under conditions in which the NF- $\kappa$ B pathway was disabled. These events were accompanied by engagement of the downstream apoptotic cascade, including activation/cleavage of procaspases-9, -3, -8, and PARP. Although the mechanism by which NF- $\kappa$ B inhibition promotes mitochondrial dysfunction is controversial, it is noteworthy that flavopiridol/HDACI-mediated mitochondrial injury was accompanied by JNK activation, an event that has been directly implicated in cytochrome c release (Tournier et al., 2000), including that triggered by HDACIs (Yu et al., 2003). Furthermore, NF- $\kappa$ B inhibition has been reported to promote JNK activation through an

XIAP-related process (Tang et al., 2001; Lewis et al., 2004). Finally, in view of evidence that p21<sup>CIP1/WAF1</sup> opposes JNK actions (Huang et al., 2003), the ability of flavopiridol to block HDACI-mediated p21<sup>CIP1/WAF1</sup> induction through both NF- $\kappa$ B-dependent and -independent mechanisms may be relevant.

In summary, the present results suggest that flavopiridol effectively blocks the ability of the HDAC inhibitors NaB and SAHA to activate NF- $\kappa$ B in human leukemia cells, and that this phenomenon contributes, at least in part, to the pronounced mitochondrial injury and apoptosis induced by this regimen. However, based upon the present results, it is probable that NF- $\kappa$ B-independent flavopiridol actions, most likely related to PTEF-b inhibition (e.g., down-regulation of XIAP, Mcl-1, and p21<sup>CIP1/WAF1</sup>), play major roles in such interactions. An additional possibility is that flavopiridol-mediated down-regulation of XIAP, Mcl-1, and p21<sup>CIP1/WAF1</sup> following HDACI exposure may be particularly lethal under conditions in which the NF- $\kappa$ B pathway is disabled. One implication of these findings is that while the search for more specific CDK inhibitors is clearly justified, less specific agents such as flavopiridol, whose actions are pleiotropic, may offer certain advantages, particularly when used in combination with other targeted agents such as HDAC inhibitors. Accordingly, efforts to determine whether similar events occur when other CDK antagonists are combined with HDAC inhibitors are currently underway.

*ACKNOWLEDGEMENTS:* This work was supported by awards CA63753, CA 93738, and CA 100866 from the National Cancer Institute, and award 6045-03 from the Leukemia and Lymphoma Society of America.

## REFERENCES

Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C, Schoonbroodt S, Goffin V, Nguyen TL, Gloire G, Carrard G, Friguet B, De Launoit Y, Burny A, Bours V, Piette J, and Van Lint C (2003) Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. *Mol Cell Biol* 23:6200-6209.

Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A and Ben-Neriah Y (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappaB inhibitor for degradation via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci U S A* 92:10599-10603.

Almenara J, Rosato RR and Grant S (2002) Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). *Leukemia*. 16:1331-1343.

Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Jeh s, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L and Chang C (2003) Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCap cells. *Cancer Res* 63:7106-7112.

Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999). Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. *EMBO J* 18:1223-1234.

Carlson BA, Dubay MM, Sauville EA, Brizuela L and Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. *Cancer Res* 56:2973-2978.

Carrozza MJ, Utley RT, Workman JL and Côté J (2003) The diverse functions of histone acetyltransferase complexes. *Trends Genet* 19:321-329.

Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderwicz AM, Peterlin BM and Price DH (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. *J Biol Chem* 275:28345-28348.

Dai Y and Grant S (2004) Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. *Curr Oncol Rep* 6:123-130.

Dai Y, Rahmani M and Grant S (2003a) An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. *Cell Cycle* 2:467-472.

Dai Y, Rahmani M and Grant S (2003b) Proteasome inhibitors potentiate leukemic cell apoptosis by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-

and NF- $\kappa$ B-dependent process. *Oncogene* 22:7108-7122.

De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH (1996). Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. *Proc Natl Acad Sci U S A*. 93:2735-2740.

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001). A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. *Clin Cancer Res* 7:2292-2300.

Gojo I, Zhang B, Fenton RG (2002). The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. *Clin Cancer Res* 11:3527-3538.

Goldberg AL and Rock K (2002) Not just research tools-proteasome inhibitors offer therapeutic promise. *Nat Med* 8:338-340.

Gray SG and Teh BT (2001) Histone acetylation/deacetylation and cancer: an “open” and “shut” case? *Curr Mol Med* 1:401-429.

Gui CY, Ngo L, Xu WS, Richon VM and Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. *Proc Natl Acad Sci U S A* 101:1241-1246.

Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W, and Schmitz ML (1998) Sesquiterpene lactones specifically inhibit activation of NF- $\kappa$ B by preventing the degradation of I $\kappa$ B- $\alpha$  and I $\kappa$ B- $\beta$ . *J Biol Chem* 273: 1288-1297.

Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H and Houghton PJ (2003) Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). 11:1491-1501.

Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Llang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA and Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. *Clin Cancer Res* 9:3578-3588.

Lee HR, Chang TH, Tebalt MJ 3<sup>rd</sup>, Senderowicz AM and Szabo E (1999) Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. *Int J Oncol* 15:161-166.

Lewis J, Burstein E, Reffey SB, Bratton SB, Roberts AB and Duckett CS (2004) Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. *J Biol Chem* 279:9023-9029.

Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR (2003). Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. *J Biol Chem* 278:18980-18989.

Nguyen DM, Schrupp WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrupp DS (2004). Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. *Clin Cancer Res* 10:1813-1825

Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM (1998). Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. *Blood* 91:458-465.

Peterson CL (2002) HDAC's at work: everyone doing their part. *Mol Cell* 9:921-922.

Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P and Grant S (2003) Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. *Oncogene* 22:6231-6242.

Richon VM, Emiliani S, Verdin E, Webb Y, Breshow R, Rifkind RA and Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc Natl Acad Sci U S A* 95:3003-3007.

Rivero JA and Adunyah SE (1998) Sodium butyrate stimulates PKC activation and



induces differential expression of certain PKC isoforms during erythroid differentiation.  
Biochem Biophys Res Commun 248:664-668.

Rosato RR, Almenara J and Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 63:3637-3645.

Rosato RR, Almenara JA, Yu C and Grant S (2004) Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 65:571-581.

Rosato RR and Grant S (2004) Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13:21-38.

Senderowicz AM (1999). Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17:313-320.

Sizemore N , Lerner N, Dombrowski N, Sakurai H and Stark GR (2002) Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappaB) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 277:3863-3869.

Takada Y and Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced

by various carcinogens and inflammatory agents through inhibition of I $\kappa$ B $\alpha$  kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. *J Biol Chem* 279:4750-4759.

Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Lin A (2001)

Inhibition of JNK activation through NF- $\kappa$ B target genes. *Nature* 414:265-266.

Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimmual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. *Science* 288:870-874.

Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S (1999). Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. *Oncogene* 18:7016-7025

Wall NR, O'Connor DS, Plescia J, Pommier Y and Altieri DC (2003) Suppression of surviving phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. *Cancer Res* 63:230-235.

Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, Dent P and Grant S (2003) Induction of apoptosis in BCR/ABL<sup>+</sup> cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. *Cancer Biol Ther* 2:544-551.

## FIGURE LEGENDS

**Figure 1.** Flavopiridol markedly inhibits activation of NF- $\kappa$ B induced by histone deacetylase inhibitors in human leukemia cells. (A) U937 cells were untreated or treated with 1 mM sodium butyrate (NaB), 100 nM flavopiridol (FP) or the combination (FP + NaB) for 24 h, after which nuclear extracts were then prepared and subjected to EMSA as described in Materials and Methods. For C + C', a 100-fold excess of unlabeled NF- $\kappa$ B oligonucleotides was added to the nuclear extract obtained from untreated cells prior to addition of labeled NF- $\kappa$ B oligonucleotides. (B) U937 cells were untreated or treated with 1.5  $\mu$ M SAHA, 100 nM FP, or the combination of FP and SAHA for 24 h. NF- $\kappa$ B DNA binding activity was determined by EMSA as described above. (C) For the supershift assay, nuclear extracts were preincubated with specific anti-p50 and anti-p65 antibodies and subjected to EMSA. Results are representative of three separate studies. For all studies, lanes were loaded with 4  $\mu$ g of protein. NF- $\kappa$ B DNA binding signals were quantified using Scion Image software (Scion Corporation). Lower panels: Mean densitometric values from 3 independent experiments were normalized to controls which were assigned an arbitrary value of 1.0. The data represent the means  $\pm$  SD (n = 3).

**Figure 2.** Inhibition of NF- $\kappa$ B activity in U937 cells transfected with and I $\kappa$ B $\alpha$  “super-repressor” mutant. U937 cells were stably transfected with an I $\kappa$ B $\alpha$  mutant (Ser32, 36/Ala) or an empty vector (pcDNA3.1) as described in Methods. Two U937 cell clones stably expressing I $\kappa$ B $\alpha$  mutants (designated 2C8 and 2H6) were then isolated and prepared. (A) Empty vector control cells and the two I $\kappa$ B $\alpha$  mutant transfectants (2C8 and 2H6) were treated with 1 mM NaB, 100 nM FP or the combination of FP and NaB, after which the nuclear extracts were prepared and subjected to EMSA as described in Methods. (B) Empty vector controls and the

two I $\kappa$ B $\alpha$  mutant transfectants (2C8 and 2H6) were treated with 1.5  $\mu$ M SAHA, 100 nM FP or the combination of FP and SAHA, after which nuclear extracts were prepared and subjected to EMSA analysis as described above. Lower panels: Densitometric analysis of signals from EMSA analysis shown above. Results represent values compared to vector controls, and are representative of three separate studies. NF- $\kappa$ B DNA binding signals were quantified and analyzed as described in Fig. 1. The data are expressed as means  $\pm$  SD (n = 3).

**Figure 3.** Stable transfection of cells with an I $\kappa$ B $\alpha$  mutant enhances FP/NaB and FP/SAHA induced apoptosis in U937 cells. U937 cells were stably transfected with I $\kappa$ B $\alpha$  mutant (Ser32, 36/Ala) or an empty vector (pcDNA3.1) as described in Methods. U937/I $\kappa$ B $\alpha$  mutant (clones 2C8 and 2H6) and /pcDNA3.1 cells were treated with 100 nM FP, the histone deacetylase inhibitors, NaB (1 mM) or SAHA (1.5  $\mu$ M), or the combination of FP/NaB (A) and FP/SAHA (B) for 24 h. Cells were stained with annexin V/PI, and apoptosis determined using flow cytometry as described in Methods. The values obtained from the annexin V assay represent the means  $\pm$  SD for three separate experiments. \*\* = values for U937/I $\kappa$ B $\alpha$  mutant cells (clones 2C8 and 2H6) significantly greater than those for empty vector controls (pcDNA3.1 cells) by the Student's t-test;  $p < 0.01$ . \*\*\* =  $p < 0.001$ .


**Figure 4.** Stable transfection of cells with an I $\kappa$ B $\alpha$  enhances FP/NaB and FP/SAHA induced mitochondrial injury in U937 cells. U937/I $\kappa$ B $\alpha$  mutant (clones 2C8 and 2H6) and /pcDNA3.1 cells were treated with 100 nM FP, NaB (1 mM) or SAHA (1.5  $\mu$ M), or the combination of FP/NaB (A) and FP/SAHA (B) for 24 h. The cytosolic S-100 fractions were prepared and subjected to Western blot assay using antibodies against cytochrome C and AIF.

Each lane was loaded with 20  $\mu$ g of protein; blots were subsequently stripped and reprobed with antibodies directed against  $\beta$ -actin to ensure equivalent loading and transfer. Two additional studies yielded equivalent results.


**Figure 5.** Stable transfection of cells with an  $I\kappa B\alpha$  enhances FP/NaB- and FP/SAHA-induced caspase activation in U937 cells. U937/ $I\kappa B\alpha$  mutant (clones 2C8 and 2H6) and /pcDNA3.1 cells were treated with 100 nM FP, NaB (1 mM) or SAHA (1.5  $\mu$ M), or the combination of FP/NaB (A) and FP/SAHA (B) for 24 h. Total cellular extracts were prepared and subjected to Western blot assay using antibodies against PARP, caspase 3, caspase 8, caspase 9, and  $\beta$ -actin as indicated. Each lane was loaded with 20  $\mu$ g of protein; blots were subsequently stripped and reprobed with antibodies directed against  $\beta$ -actin to ensure equivalent loading and transfer. Two additional studies yielded equivalent results.

**Figure 6.** Stable transfection of RelA/p65 siRNA enhances FP/NaB- and FP/SAHA- induced apoptosis in U937 cells. U937 cells were stably transfected with RelA/p65 siRNA or an empty vector (3.1-H1 hygro) as described in Methods. Comparison of the expression of RelA/p65 in U937/p65 siRNA and U937/3.1-H1 hygro cells is shown by Western blot (A). U937/p65 siRNA (p65) and /3.1-H1 hygro (3.1) cells were treated with FP (100 nM), NaB (1 mM) or SAHA (1.5  $\mu$ M), or the combination of FP/NaB (B) and FP/SAHA (C) for 24 h. Cells were stained with annexin V/PI, and apoptosis was determined using flow cytometry. The values obtained from annexin V assays represent the means  $\pm$  SD for three separate experiments. \*\* = values for RelA/p65 siRNA cells significantly greater than those for empty vector controls (3.1) by the Student t-test;  $p < 0.01$ .


**Figure 7.** Stable transfection with an I $\kappa$ B $\alpha$  mutant enhances FP/NaB and FP/SAHA-induced activation of phospho-JNK and down-regulation of XIAP, p21<sup>CIP1/WAF1</sup>, and Mcl-1. U937/I $\kappa$ B $\alpha$  mutant (2C8 and 2H6) and /pcDNA3.1 cells were treated with 1 mM NaB, 100 nM FP or the combination of FP/NaB (A). Alternatively, transfected cells were also treated with 1.5  $\mu$ M SAHA, 100 nM FP or the combination of FP/SAHA (B). Total cellular extracts were prepared and subjected to Western blot assay using antibodies against phospho-JNK, JNK, XIAP, Mcl-1, p21<sup>CIP1/WAF1</sup>, p27<sup>KIP1</sup>, and  $\beta$ -actin. Each lane was loaded with 20  $\mu$ g of protein; blots were subsequently stripped and re-probed with antibodies to actin to ensure equivalent loading and transfer. Two additional studies yielded equivalent results.




**Figure 1**








**Figure 3**



**Figure 4**



**Figure 5**





Figure 6



**Figure 7**